X4 Pharmaceuticals
Christophe Arbet-Engels, MD, PhD, MBA, currently serves as Chief Medical Officer at X4 Pharmaceuticals since August 2023 and is also a member of the Board of Tutors in Biochemical Sciences at Harvard University, where instruction focuses on critical thinking in life sciences. Previously, Christophe held Chief Medical Officer positions at Neurogastrx, Inc. and MILLENDO THERAPEUTICS, and has extensive experience in the biopharmaceutical sector, including roles at POXEL and as an Executive Consultant at MedNest. Additional roles include leadership positions at Biogen and Boehringer-Ingelheim overseeing medical development and life cycle strategies across various therapeutic areas. Education includes an MD from Paris-Sud University, a PhD in Endocrinology/Diabetes from Université Paris Cité, an MBA in Finance from Rutgers University - Newark, and a leadership certificate from The Wharton School.
This person is not in any teams
X4 Pharmaceuticals
3 followers
X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance.